cyrilzakka/clinical-trials huggingface dataset:
The Relationship Between Education Status and Care Burden of Mothers of Individuals With Cerebral Palsy

This study, examines how maternal education affects caregiving burdens for children with cerebral palsy. Cerebral palsy requires long-term, intensive care, often leading to significant physical, emotional, and financial strain on caregivers. The study aims to assess whether higher maternal education is associated with lower care burdens, possibly due to increased access to resources or coping strategies, and whether lower educational levels result in greater challenges. A survey, combined with standardized measures such as the Caregiver Burden Scale, will be used to quantify the caregiving burden. The results are expected to inform policies or interventions aimed at reducing caregiver strain.

This study titled "The Relationship Between the Education Status of Mothers and the Care Burden of Individuals with Cerebral Palsy" aims to explore how the education level of mothers influences their caregiving responsibilities and burdens while caring for individuals with cerebral palsy. Cerebral palsy, a neurological disorder affecting movement and muscle tone, often requires lifelong caregiving, which can be physically, emotionally, and financially demanding.

The study seeks to investigate whether mothers with higher levels of education experience lower care burdens due to greater access to resources, knowledge of coping strategies, or better healthcare utilization. Conversely, the study will also examine if mothers with lower educational attainment face more significant challenges due to limited access to support systems or information.

The research will involve a mixed-methods approach, including a survey to assess the education level of mothers and the care burden they experience. Specific tools to measure care burden, such as the Caregiver Burden Scale, will be employed. The findings aim to provide insights into the role of education in mitigating caregiving challenges and inform potential interventions or policies that could support caregivers in these situations.

Eligibility Criteria:
Inclusion Criteria:

* Having a child who is receiving education in special education institutions
* The child's diagnosis was made at least 6 months ago
* The disabled individuals must be between the ages of 0-18

Exclusion Criteria:

-
Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer

The purpose of this research study is to determine if saliva and oral swab samples can be used to detect human papillomavirus in patients with cancer. In this study, the methods required to detect human papillomavirus will be developed and tested in samples collected from patients with oropharyngeal squamous cell carcinoma and compared to samples collected from participants without cancer.

To validate the detection of human papillomavirus 16 and 18 and reference gene ACTB in saliva and buccal swab samples obtained from patients with oropharyngeal squamous cell carcinoma (OPSCC) using the LAMP/CRISPR/electrochemical workflow.

Eligibility Criteria:
Inclusion Criteria (Patients with Cancer);

* Patients must have histologically confirmed oropharyngeal squamous cell carcinoma without prior treatment. A pathology report should be referenced/available.
* Patients with p16 positive oropharyngeal squamous cell carcinoma.
* Age 39 to 59 years.
* Ability to understand and the willingness to sign an IRB-approved informed consent document directly.

Inclusion Criteria (Healthy Subjects)

* Age 39 to 59 years.
* Ability to understand and the willingness to sign an IRB-approved informed consent document directly.

Exclusion Criteria (Patients with Cancer)

* Patients with diagnoses of other cancers.
* Patients with current or previous diagnosis with HPV+ infection status for cervical cancer or other cancers.

Exclusion Criteria (Healthy Subjects)

* Previous diagnosis of cervical cancer or other cancers.
* Presence of known active oral infections of viral, fungal, or bacterial etiology except for gingivitis, periodontitis, or periapical abscess. Participants with known gingivitis, periodontitis, or periapical abscess are included.
Identification by Transcriptomic Approach of New Prognostic and Predictive Markers in a Cohort of Atypical Meningiomas

Determine by a transcriptomic approach new prognostic and predictive markers in atypical meningiomas (WHO grade II).

Retrospective observational study, on a cohort of 85 atypical meningiomas. Transcriptomic study first, on cryopreserved tumor samples. Then identify, thanks to the transcriptomic study, prognostic and predictive factors (study of the link between the quantity of certain RNA transcripts and progression-free survival). Finally, set up immunohistochemical applications, which can be used routinely by the pathologist.


Eligibility Criteria:
Inclusion Criteria:

* Primary operated patients for an atypical meningioma (WHO grade II) in the Neurosurgery department of the University Hospital of Nancy.
* At least one postoperative follow-up visit.
* Adult patients (\>18 yo) at the time of the intervention.
* Surgical excision.

Exclusion Criteria:

* History of meningioma in the same location.
* Neo-adjuvant treatment.
* Absence of non-objection form.
Project Fit:a School- and Community-based Obesity Intervention

Project FIT is a collaboration between the public school system, local health systems, physicians, neighborhood associations, businesses, faith-based leaders, community agencies and university researchers to develop a multi-faceted approach to promote physical activity and healthy eating toward the general goal of preventing and reducing childhood obesity among children in Grand Rapids, MI, USA. There are four overall components to Project FIT: school, community, social marketing, and school staff wellness - all that focus on: 1) increasing access to safe and affordable physical activity and nutrition education opportunities in the schools and surrounding neighborhoods; 2) improving the affordability and availability of nutritious food in the neighborhoods surrounding the schools; 3) improving the knowledge, self-efficacy, attitudes and behaviors regarding nutrition and physical activity among school staff, parents and students; 4) impacting the 'culture' of the schools and neighborhoods to incorporate healthful values; and 5) encouraging dialogue among all community partners to leverage existing programs and introduce new ones.


Eligibility Criteria:
Inclusion Criteria:

* enrolled in participating school district in grades 1-5.

Exclusion Criteria:

* None
Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX

This is a study to compare the efficacy, safety and immunogenicity of AVT05 versus EU-Simponi® in combination with methotrexate (MTX) in subjects with moderate to severe rheumatoid arthritis (RA).

The study will consist of up to 4-week Screening Period, a 48-week Treatment Period, and a 4-week Safety Follow-up Period.


Eligibility Criteria:
Inclusion Criteria:

* Subjects diagnosed with active RA according to ACR/EULAR 2010 classification criteria
* Subjects diagnosed with moderately to severe active RA as defined by ≥ 6 swollen (out of 66) and ≥6 tender (out of 68) joint counts, CRP \>1mg/l and with at least one of positive rheumatoid factor, positive anti-citrullinated peptide antibodies and/or evidence of 1 joint erosion of hands, wrist of dominant hand or feet at screening
* Subjects must have taken methotrexate for ≥12 weeks

Exclusion Criteria:

* Prior treatment with biologics or Janus kinase inhibitors that may be used as disease-modifying anti-rheumatic drugs
* Any past or concurrent medical conditions that could potentially increase the subject's risks or that would interfere with the study evaluation, procedures or study completion
* Major chronic inflammatory disease or connective tissue disease other than RA or any active autoimmune disease
* Presence of chronic obstructive pulmonary disease
* Presence of chronic heart failure NYHA class III or IV
Dose-Finding Study of M516102 in the Treatment of Pruritus Associated With Atopic Dermatitis

This study is to investigate the efficacy and safety of M516102 and to evaluate the dose response relationship of M516102 and placebo, in the treatment of pruritus associated with atopic dermatitis.


Eligibility Criteria:
Inclusion Criteria:

1. Male or female patients (aged 18-65 years) with a diagnosis of AD.
2. Female patients of child bearing potential must be using a medically acceptable form of contraception.
3. Patients who are able and willing to give signed informed consent.
4. Patients who have pruritus exceed the reference range.

Exclusion Criteria:

1. Patients who have a history of allergy to hydrocortisone.
2. Patients who have a history of relevant drug hypersensitivity.
3. Patients who have a history of contact dermatitis induced by a topical steroid.
4. Patients who are taking, and who are unwilling not to take, any medications or therapy prohibited by the protocol for the complete duration of the study.
5. Patients who have a history or presence of any cancer.
6. Patients who have any renal or liver insufficiency, or clinically significant cardiac, renal or hepatic disease.
7. Patients who, in the opinion of the investigator, are not deemed eligible as determined by medical history, physical examination or clinical laboratory safety tests.
8. Patients who have pruritus associated with conditions other than AD.
9. Patients who have pruritus only on the face and head.
10. Patients who, in the opinion of the investigator, have clinically relevant history or presence of any disease, or surgical history other than AD which is likely to affect the conduct of the study.
11. Patients who have used M5161(active ingredient of M516102).
12. Patients who cannot communicate reliably with the investigator.
13. Patients who are pregnant or lactating.
14. Patients who have used any IMP and/or participated in any clinical trial within 3 months.
Efficacy of Single Incision (Embryonic NOTES) Laparoscopic Colorectal Surgery

Laparoscopic colon surgery has been performed widely. As a minimal invasive approach, single incision (Embryonic NOTES) colon surgery has been attempted.

However, there are not sufficient evidences for single incision colon surgery in colon cancer.

The investigators are researching the efficacy and safety of single incision laparoscopic sigmoidectomy in sigmoid colon cancer.

After several randomized clinical trials, laparoscopic colon surgery has been performed widely. As a minimal invasive approach, single Incision (Embryonic NOTES) colon surgery has been attempted. Several studies reported the feasibility of single incision colon surgery.However, there are not sufficient evidences for single incision colon surgery, especially in colon cancer.

The investigators are researching the efficacy and safety of single incision laparoscopic sigmoidectomy in sigmoid colon cancer. Harvested numbers of lymph node will be assessed for the efficacy and postoperative morbidity and mortality will be assess for the safety.

Eligibility Criteria:
Inclusion Criteria:

* Patients should sign a written informed consent
* Age between 18-80
* Patients have sigmoid colon cancer that was proved by pathology
* Adequate bone marrow function Hb ≥ 10g/dl (after treatment for simple iron deficiency anemia) WBC ≥ 3,000/mm3 PLT ≥ 100,000/mm3
* Adequate kidney function Creatinine ≤ 1.5 mg/dl
* No remarkable evidence of heart dysfunction and lung dysfunction

Exclusion Criteria:

* Distant metastasis
* Tumor diameter \> 5 cm
* Other organ invasion
* Intestinal obstruction and stent insertion status
* Patient was used steroid
* Patients undergo emergency surgery with multiple symptoms
* Other organ cancer history (except who had radical excision for skin cancer)
* Presence of other serious disease
* Mentally ill patients
* Legally unable to participate in clinical trial
* Lactating or pregnant women
* Patients who will obviously fail to regular follow-up visit or will be off study voluntarily
* Not eligible to participate for other reasons by doctor's decision
Effect of Body Tilting on Diaphragm Excursion and Thickness in the Stroke Patients With Tracheotomy by Ultrasonography

The purpose of this study was to examine whether if the effect of standing with assistance of the tilt table on diaphragm excursion and thickness in the stroke patients with tracheotomy.

40-45 stroke patients with tracheotomy were passive tilting (α=0°, 30°, 60°) by an electric tilt table in the random order. The diaphragm excursion and thickness were measured by ultrasonography on three tilting during the quiet breathing. Besides, the intraclass correlation coefficient (ICC) were calculated to assess the reliability of the diaphragm ultrasonography in this population.

Eligibility Criteria:
Inclusion Criteria:

1. currently diagnosed with ischemic or hemorrhagic stroke by CT or MRI;
2. right unilateral or bilateral limb with hemiparesis;
3. age over 18 years;
4. BMI\<35 kg/m2;
5. within 2 weeks to 12 months；
6. the tracheotomy tube replacement;
7. non first time standing assisted with tilt table.

Exclusion Criteria:

1. undergoing mechanical ventilation;
2. postural hypotension;
3. myocardial infarction in the first 3 months;
4. deep vein thrombosis;
5. angina or acute heart failure;
6. complicated with other primary pulmonary diseases, such as tuberculosis,；pneumothorax, and chronic obstructive pulmonary disease and so on;
7. a past episode of abdominal or chest surgery.
Corticosteroid Injection as a Predictor of Outcome in Carpal Tunnel Release

This study will investigate whether symptomatic improvement following carpal tunnel corticosteroid injection can be correlated to symptomatic improvement following carpal tunnel release and therefore serve as a prognostic indicator.

Clinical question: Does response to corticosteroid injection in CTS predict outcomes of surgical treatment?

Secondary Questions:

1. Can we confirm previous retrospectively collected data that a certain percentage of conservatively managed patients with steroid injection will avoid surgery, and that patients who undergo surgery will have better outcomes than those who do not.
2. Are there differences between worker's compensation and non-worker's compensation patients with regard to the primary clinical question?
3. What are Carpal Tunnel Release outcomes for the subset of patients with negative electrophysiologic studies?
4. What are the outcomes of patients who undergo carpal tunnel release vs. those who choose not to undergo carpal tunnel release?

A prospective cohort design study is the appropriate study design in order to measure the association between a predictor (response to injection) and outcome (response to surgery).

Carpal Tunnel Syndrome is a painful condition that is caused by compression of the median nerve in the wrist. Symptoms usually are pain, weakness, or numbness in the hand and wrist, radiating up the arm. Corticosteroid injections have been utilized in the conservative management of carpal tunnel syndrome for several decades. They have been shown to be relatively safe with a very low reported complication rate. Recent efforts in the literature have shown they are efficacious for a majority of patients although their effects are usually transient. Several studies have attempted to show a predictive value of corticosteroid injection with regard to who will ultimately benefit from carpal tunnel release. There is a trend towards positive predictability with several retrospective studies showing that patients who have a clinical benefit from steroid injection are more likely to have a successful outcome from carpal tunnel release. Carpal tunnel release remains the definitive treatment option for carpal tunnel syndrome, and a clinical test which could give the practitioner and patient additional information regarding likelihood of successful outcome of surgery would be a valuable prognostic tool.

Eligibility Criteria:
Inclusion Criteria:

* Patients with a clinical diagnosis of carpal tunnel syndrome
* English speaking patients only

Exclusion Criteria:

* Patients less than 18 years old
* Patients who are pregnant by patient report or intending to become pregnant during the study
* Patients unwilling or unable to return for follow-up visits prescribed by the study protocol.
* Patients who qualify for inclusion in the study, but refuse to participate.
* Patients with evidence of thenar atrophy on exam
* Patients with a diagnosis of peripheral neuropathy or other neuropathy.
* Patients with previous ipsilateral carpal tunnel injection or release.
The Grow to Recovery Train-the-Trainer Program

Recovery-oriented services are becoming popular in the mental health field. However, recovery-oriented services are still in the beginning stages in Taiwan. Many professionals do not know how to implement recovery-oriented services. More effort should be made to improve mental health services in Taiwan. Hence, the aim of this study is to examine the effectiveness of the Grow to Recovery Train-the-Trainer program.

The study will verify the effectiveness of the Train-the-Trainer program with the cluster randomized controlled trial design. The resesarchers will recruit 10 psychiatric rehabilitation organizations, including 80 mental health professionals and 160 people with mental illness. The professionals of the intervention group will receive a online training and then conduct a 5-month recovery group. The organization-level and service user assessments will be collected to examine the overall outcomes.

Eligibility Criteria:
Inclusion Criteria:

Professionals:

1. working in the community psychiatric rehabilitation organizations
2. being willing to participate in the study

People with mental illness

1. having a diagnosis of mental illness
2. living in the community
3. being age 20 yr or older
4. receiving services from the collaborating organizations
5. filling out the scales independently
6. being able to participate in a recovery group and follow the group rules

Exclusion Criteria:

* attending another recovery-related group
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

This is a multicenter, prospective, randomized controlled clinical study comparing the efficacy and safety of CLAG+VEN and CLAG regimens in relapsed/refractory(r/r) AML.

The efficacy and prognosis of relapsed/refractory(r/r) AML are very poor, and there is no standard chemotherapy regimen were defined for r/r AML. Cladribine, a purine analogue, exerts cytotoxic, proapoptotic, and antiproliferative effects on AML cells. Previous studies have confirmed the efficacy of cladribine in the treatment of r/r AML, with a response rate of 30-45%.Our previous experience has shown that CLAG in combination of venetoclax are effective with tolerable toxicity profiling. However, there is a lack of multicenter, prospective, randomized controlled trials to further confirm the results. Therefore, a clinical study is planned to evaluate the efficacy and safety of CLAG+VEN compared to CLAG in r/r AML who were eligible for intensive therapy.

Eligibility Criteria:
Inclusion Criteria:

1. Diagnosed of AML according to the World Health Organization (WHO) classification.
2. All patients should aged 18 to 65 years.
3. Diagnosed of relapsed and refractory AML, according to The guidelines for diagnosis and treatment of relapse /refractory acute myelogenous leukemia in China（2023）
4. Diagnostic criteria for relapsed AML: Leukemia cells reappear in the peripheral blood or primitive cells in the bone marrow ≥ 5% (excluding other reasons such as bone marrow regeneration after consolidation chemotherapy) after CR, or leukemia cell infiltration appears outside the marrow.
5. Diagnostic criteria for refractory AML: The newly diagnosed patients who failed to respond to two courses of standard treatment; Patients who relapsed within 12 months after consolidation intensive therapy; Patients who relapsed after 12 months and failed to respond to conventional chemotherapy; Patients with two or more recurrences; Patients with persistent extramedullary leukemia.
6. The score of Eastern Cooperative Oncology Group (ECOG) is 0-2.
7. Renal function: creatinine clearance rate ≥ 30ml/min.
8. Liver function: ALT\<5 times normal value, bilirubin\<3 times normal value.
9. Predicted survival ≥ 3 months.
10. Able to accept oral Venetoclax.
11. Sign an informed consent form and be able to understand and follow the procedures required by this protocol.

Exclusion Criteria:

1. Diagnosed of acute promyelocytic leukemia (AML-M3)
2. Patients with central nervous system (CNS) invasion.
3. Cardiac function \< grade 2.
4. Known human immunodeficiency virus (HIV) infection.
5. Other clinically significant uncontrolled conditions, including but not limited to: a. uncontrolled or active systemic infections (viruses, bacteria, or fungi); b. Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) requiring treatment; c. Secondary tumors requiring active treatment.
6. Allergy to experimental drugs.
7. Pregnant and lactating women.
8. Patients who ineligible for the study according to the investigator's assessment.
High Frequency Stimulation of the GPi or Thalamus in Tourette's Syndrome

Tourette's syndrome is a disabling neuropsychiatric disorder with major psychosocial consequences in some patients. The pathophysiology is still unknown. Some data suggest an dysfunction of limbic circuits in basal ganglia. The aim of this study is to evaluate the effect of high frequency stimulation of the internal part of the globus pallidus and/or parafascicular-median centre of the thalamus, two structures implicated in the limbic circuit, in patients with severe Tourette's syndrome.


Eligibility Criteria:
Inclusion Criteria:

* Tourette's syndrome (DSM IV)
* inducing a disability in the social and personal life
* No improvement with medical treatment
* Severe self suffering

Exclusion Criteria:

* Cognitive impairment (MMS \< 24)
* Depression